Collection of Blood From Patients With Cancer

Background:

Correlative studies performed on biospecimens of human subjects can be used to investigate the biology of solid tumors, inform the development of new strategies for treating those cancers, and evaluate these new therapeutic approaches. Specific areas of interest include, but are not limited to:
the underlying mechanisms of tumor-specific immune response and suppression in cancer patients
genetic and molecular profiling of tumors through circulating tumor cell (cTC), circulating DNA, and tissue analysis
investigation of potential early diagnostic and prognostic indicators for solid tumors such as cTCs and miRNA expression of serum exosomes
identification of mechanisms of drug-related adverse events and correlation with clinical parameters
the role of commensal gut microbiota in both the innate and adaptive responses to tumors as well as with the use of anticancer agents

Objectives:

Analyze biospecimens such as tissue, urine, saliva, stool and blood components, which include serum, leukocytes, peripheral blood mononuclear cells (PBMC), and circulating tumor cells (cTC), of human subjects.
Correlate analysis results with clinical parameters such as demographics, toxicities, and treatment outcomes.
Undertake genetic analysis of both prokaryotic and eukaryotic samples for advanced mutational analysis.

Eligibility:

Patients and healthy volunteers whose biospecimens are of interest to NIH investigators.
18 years of age or older.

Design:

- Subject cases will be evaluated by NCI or Interventional Radiology, NIH Clinical Center personnel. Blood, tissue, urine, saliva or other samples may be collected at the initial visit and at follow-up visits.